Skip to content

The efficacy and safety of QFR-guided complete revascularization in patients with STEMI and multivessel disease: a pilot randomised controlled trial

The efficacy and safety of QFR-guided complete revascularization in patients with STEMI and multivessel disease: a pilot randomised controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100044120
Enrollment
Unknown
Registered
2021-03-11
Start date
2021-03-03
Completion date
Unknown
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

QFR-G-CR:Patients underwent QFR measurements of non-IRA lesions, with the standard vessel diameter set to >= 2.0 mm and angiographic DS% between 50-90%.
IRA-only PCI:Patients, in the IRA only revascularization patient population, received PPCI and no other invasive procedures. Instead, they received non-invasive medical therapy.

Sponsors

Department of Cardiology, Affiliated Hospital of Hebei University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult STEMI patients; 2. undergo primary PCI within 24h of symptom onset; 3. hemodynamically stable after the PPCI procedure; 4. had >=1 lesion, with a percent diameter stenosis (DS%) between 50-90% in >= 1 non-IRAs, with a > 2.0 mm standard vessel diameter by visual estimation or quantitative coronary angiography.

Exclusion criteria

Exclusion criteria: (1) Severe heart failure (HF) or cardiogenic shock (New York Heart Association [NYHA] >= III); (2) strongly weakened kidney function: creatinine > 150 µmol/L or Cockcroft-Gault calculated glomerular filtration rate (GFR) 90%) with a TIMI flow grade <= 2 in the non-IRA; (7) complications post IRA therapy; (8) severe valve dysregulation; (9) with prior coronary artery bypass grafting (CABG); and (10) Coronary artery ostium or segments with severe tortuosity or with diffuse and distal disease of any interrogated vessel regarded as not conducive to QFR measurement.

Design outcomes

Primary

MeasureTime frame
Event rate;

Countries

China

Contacts

Public ContactZhang Jing

Affiliated Hospital of Hebei University

zhanjingmd@163.com+86 17325387285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026